This article is more than 5 years old. Information may no longer be current.

Allergan receives FDA approval for Restasis Multidose

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan announced it has received FDA approval for Restasis Multidose, a preservative-free, multidose bottle offering the same formulation as Restasis for patients with chronic dry eye who need to make more of their own tears.

Restasis Multidose includes a new multidose bottle that uses less plastic than a package of single-use vials, according to a company press release. It is designed with a unidirectional valve and air filter technology, eliminating the need for a preservative.

Restasis (cyclosporine ophthalmic emulsion 0.05%) helps increase the eyes’ natural ability to produce tears, which may be affected by inflammation due to chronic dry eye.

Restasis Multidose will be the same price as a package of single-use vials, the release said.